Clinical Efficacy and Safety of Fanhdi ®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain : A Retrospective Study
| Autor: | Jiménez-Yuste, Víctor, Alvarez-Román, María Teresa, Palomo Bravo, Ángeles, Galmes, Bernardo J., Nieto Hernández, Maria del Mar, Benítez Hidalgo, Olga, Marzo Alonso, Cristina, Pérez González, Noelia Florencia, Coll, Julia, Núñez, Ramiro, Carrasco, Marina, García-Candel, Faustino, Gonzalez-Porras, Jose Ramon, Hernández García, Carmen, Varó Castro, Maria José, Mir, Roser, Universitat Autònoma de Barcelona |
|---|---|
| Přispěvatelé: | UAM. Departamento de Medicina, Institut Català de la Salut, [Jiménez-Yuste V, Alvarez-Román MT] Department of Hematology and Hemotherapy, Hospital Universitario La Paz, Autónoma University, Madrid, Spain. [Palomo Bravo Á] Hematology Service, Hospital Materno-Infantil de Málaga, Málaga, Spain. [Galmes BJ] Hematology Service, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Nieto Hernández MDM] Hematology and Hemotherapy Service, Complejo Universitario de Jaén, Jaén, Spain. [Benítez Hidalgo O] Servei d’Hematologia i Hemoteràpia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male congenital hereditary and neonatal diseases and abnormalities Adolescent Medicina Blood Loss Surgical Hemorrhage Hemostatics surgery Young Adult von willebrand disease Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Blood Coagulation Factors::von Willebrand Factor [CHEMICALS AND DRUGS] hemic and lymphatic diseases enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de la coagulación sanguínea::trastornos de la coagulación sanguínea hereditarios::enfermedades de von Willebrand [ENFERMEDADES] Humans Diseases of the circulatory (Cardiovascular) system Plasma-derived von willebrand factor/factor VIII concentrate Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Blood Coagulation Disorders Inherited::von Willebrand Diseases [DISEASES] Other subheadings::/therapeutic use [Other subheadings] Child Aged Retrospective Studies Sang - Coagulació - Factor VIII Factor VIII Otros calificadores::/uso terapéutico [Otros calificadores] Prophylaxis Bleeding plasma-derived von willebrand factor/factor VIII concentrate Hematology General Medicine Middle Aged bleeding Von willebrand factor von willebrand factor Drug Combinations von Willebrand Diseases aminoácidos péptidos y proteínas::proteínas::proteínas sanguíneas::factores de coagulación de la sangre::factor de von Willebrand [COMPUESTOS QUÍMICOS Y DROGAS] Spain RC666-701 Female Surgery Von willebrand disease prophylaxis Malaltia de von Willebrandt - Tractament |
| Zdroj: | Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022) Scientia |
| Popis: | To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients. Methods: A retrospective, multicentric, observational study of VWD patients treated with Fanhdi®, a pdVWF/FVIII concentrate, from January 2011 to December 2017 was conducted at 14 centers in Spain. Efficacy and safety were evaluated for acute bleeding episodes, for prevention of bleeding in surgeries, and for secondary long-term prophylaxis. Seventy-two eligible patients, type 1, 2, 3 VWD (25%/38.9%/36.1%) were treated for spontaneous and traumatic bleeding (140 episodes, n = 41 patients), to prevent surgical bleeding (69 episodes, n = 43 patients); and for secondary long-term prophylaxis (18 programs, n = 13 patients). Replacement therapy with pdVWF/FVIII showed an excellent to good clinical efficacy in 96.7% of the bleeding episodes, 100% during surgical procedures and 100% during prophylaxis. No adverse events (AEs), nor serious AEs related to the product were observed. Conclusions: Fanhdi® was effective, safe and well tolerated in the management of bleeding episodes, the prevention of bleeding during surgeries, and for secondary long-term prophylaxis in VWD patients The author(s) disclosed receipt of the followingfinancial support forthe research, authorship, and/or publication of this article: This workwas supported by Grifols, manufacturer of the pdVWF/FVIII,Fanhdi® |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|